Literature DB >> 26028636

Chronic thromboembolic pulmonary hypertension: a distinct disease entity.

Irene Lang1.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension (PH). One disease hypothesis is that CTEPH results from the non-resolution of venous thromboembolism. CTEPH is characterised by the presence of obstructive fibrotic thromboembolic material in the major pulmonary vessels, with concomitant microvascular arteriopathy, resulting in progressive PH. The clinical presentation of CTEPH is similar to pulmonary arterial hypertension with nonspecific symptoms, but it is distinguished from pulmonary arterial hypertension by the presence of mismatched segmental defects on the ventilation/perfusion scan. The exact prevalence and incidence of CTEPH are unknown, but are thought to have been underestimated in the past. CTEPH is unique among the subgroups of PH in that it is potentially curable with pulmonary endarterectomy, a surgical intervention intended to remove the occlusive material from the pulmonary vasculature. However, in some patients the obstructions are technically inaccessible or the risk/benefit ratios are unfavourable, making the condition inoperable. It is thought that the involvement of the smaller, more distal vessels is a target for medical treatment. Untreated, CTEPH may result in right heart failure and death. The pathophysiological mechanisms which cause CTEPH are complex and have not yet been fully elucidated.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2015        PMID: 26028636     DOI: 10.1183/16000617.00001115

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  22 in total

1.  The link between chronic thromboembolic pulmonary hypertension and sarcoidosis: association or visual masquerade?

Authors:  Rajive Tandon; Robert P Baughman; Janice Stanley; Ali A Khan
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.

Authors:  Evandro M Neto-Neves; Mary B Brown; Maria V Zaretskaia; Samin Rezania; Adam G Goodwill; Brian P McCarthy; Scott A Persohn; Paul R Territo; Jeffrey A Kline
Journal:  Am J Pathol       Date:  2017-02-07       Impact factor: 4.307

3.  Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Monika Sznajder; Olga Dzikowska-Diduch; Katarzyna Kurnicka; Marek Roik; Dominik Wretowski; Piotr Pruszczyk; Maciej Kostrubiec
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 4.  Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Authors:  Victor R Gordeuk; Oswaldo L Castro; Roberto F Machado
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

5.  Post pulmonary embolism syndrome: a common, underdiagnosed complication that is not well recognised.

Authors:  Alexander Sanders; Max Matonhodze
Journal:  BMJ Case Rep       Date:  2019-02-22

6.  Balloon pulmonary angioplasty improves interventricular dyssynchrony in patients with inoperable chronic thromboembolic pulmonary hypertension: a cardiac MR imaging study.

Authors:  Yuzo Yamasaki; Michinobu Nagao; Kohtaro Abe; Kazuya Hosokawa; Satoshi Kawanami; Takeshi Kamitani; Torahiko Yamanouchi; Koshin Horimoto; Hidetake Yabuuchi; Hiroshi Honda
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-26       Impact factor: 2.357

Review 7.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

8.  Outcomes of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension at a Single Center in Taiwan.

Authors:  Yu-Jhou Chen; Chien-Te Ho; Feng-Chun Tsai; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Kuang-Tso Lee; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2019-03       Impact factor: 2.672

9.  Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Cheng-Hsuan Tsai; Cho-Kai Wu; Ping-Hung Kuo; Hsao-Hsun Hsu; Zheng-Wei Chen; Juey-Jen Hwang; Chi-Lun Ko; Yu-Sen Huang; Yen-Hung Lin
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

10.  Balloon pulmonary angioplasty in a patient with prostate cancer and chronic thromboembolic pulmonary hypertension.

Authors:  Yolanda Bryce; Ernesto Santos
Journal:  Clin Imaging       Date:  2018-04-06       Impact factor: 1.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.